Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial

Sandborn, W. J.; Hanauer, S. B.; Rutgeerts, P.; Fedorak, R. N.; Lukas, M.; MacIntosh, D. G.; Panaccione, R.; Wolf, D.; Kent, J. D.; Bittle, B.; Li, J.; Pollack, P. F.
September 2007
Gut;Sep2007, Vol. 56 Issue 9, p1232
Academic Journal
Background: Adalimumab induced clinical remission after four weeks in patients with active Crohn's disease in the CLASSIC I trial. Objective: To evaluate long term efficacy and safety of adalimumab maintenance therapy in Crohn's disease in a follow-on randomised controlled trial (CLASSIC II). Methods: In the preceding CLASSIC I trial, 299 patients with moderate to severe Crohn's disease naive to tumour necrosis factor antagonists received induction therapy with adalimumab 40 mg/20 mg, 80 mg/40 mg, or 160 mg/80 mg, or placebo, at weeks 0 and 2. In all, 276 patients from CLASSIC I enrolled in CLASSIC II and received open-label adalimumab 40 mg at weeks 0 (week 4 of CLASSIC I) and 2; 55 patients in remission at both weeks 0 and 4 were re-randomised to adalimumab 40 mg every other week, 40 mg weekly, or placebo for 56 weeks. Patients not in remission at both weeks 0 and 4 were enrolled in an open-label arm and received adalimumab 40 mg every other week. With non-response or flare, these patients could have their dosages increased to 40 mg weekly. Patients in the randomised arm with continued non-response or disease flare could switch to open-label adalimumab 40 mg every other week and again to 40 mg weekly. The primary end point was maintenance of remission (CDAI < 150) in randomised patients through week 56. Results: Of 55 patients randomised at week 4, 79% who received adalimumab 40 mg every other week and 83% who received 40 mg weekly were in remission at week 56, v 44% for placebo (p<0.05). In all, 204 patients entered the open-label arm. Of these, 93 (46%) were in clinical remission at week 56. Adalimumab was generally well-tolerated in all patients. Conclusions: Adalimumab induced and maintained clinical remission for up to 56 weeks in patients with moderate to severe Crohn's disease naive to anti-TNF treatment.


Related Articles

  • Certolizumab Pegol for the Treatment of Crohn's Disease. Sandborn, William J.; Feagan, Brian G.; Stoinov, Simeon; Honiball, Pieter J.; Rutgeerts, Paul; Mason, David; Bloomfield, Ralph; Schreiber, Stefan // New England Journal of Medicine;7/19/2007, Vol. 357 Issue 3, p228 

    Background: Certolizumab pegol is a pegylated humanized Fab' fragment that binds tumor necrosis factor a. Methods: In a randomized, double-blind, placebo-controlled trial, we evaluated the efficacy of certolizumab pegol in 662 adults with moderate-to-severe Crohn's disease. Patients were...

  • Use of Infliximab in Particular Clinical Settings: Management Based on Current Evidence. Papa, Alfredo; Mocci, Giammarco; Bonizzi, Michele; Felice, Carla; Andrisani, Gianluca; De Vitis, Italo; Guidi, Luisa; Gasbarrini, Antonio // American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1575 

    With the increasingly widespread use of the anti-tumor necrosis factor-α agent infliximab for the treatment of Crohn's disease and ulcerative colitis, there have been some concerns raised about the potential consequences of such therapy in particular clinical settings. In this review, we...

  • Certolizumab pegol: Pegylated TNF-alpha blocker for Crohn's disease. Tanzi, Maria G. // Pharmacy Today;Jun2008, Vol. 14 Issue 6, p18 

    The article reports on the approval of the first and only pegylated tumor necrosis factor (TNF)-alpha blocker in the U.S. The medication was approved in April 2008. It is used in the treatment of Crohn's disease and for maintaining clinical response in adult patients with moderate to severe...

  • Anti-TNF-α treatment for post-anastomotic ulcers and inflammatory bowel disease with Crohn's-like pathologic changes following intestinal surgery in pediatric patients. Freeman, Jennifer; Rabah, Raja; Hirschl, Ronald; Maspons, Aldo; Meier, Donald; Teitelbaum, Daniel // Pediatric Surgery International;Jan2015, Vol. 31 Issue 1, p77 

    Purpose: To report a previously poorly recognized process of secondary formation of inflammatory bowel disease (IBD)-like process, specifically Crohn's-like changes in pediatric surgery patients who underwent major small bowel and colorectal surgery. We describe potential etiologies, presenting...

  • Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Hanauer, Stephen B. // Gut;Sep2007, Vol. 56 Issue 9, p1181 

    Since the introduction of infliximab to treat Crohn's disease, combination therapy, with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

  • Infliximab Therapy Inhibits Inflammation-Induced Angiogenesis in the Mucosa of Patients With Crohn's Disease. Rutella, Sergio; Fiorino, Gionata; Vetrano, Stefania; Correale, Carmen; Spinelli, Antonino; Pagano, Nico; Arena, Vincenzo; Maggiano, Nicola; Repici, Alessandro; Malesci, Alberto; Danese, Silvio // American Journal of Gastroenterology;Apr2011, Vol. 106 Issue 4, p762 

    OBJECTIVES:Inflammation-driven angiogenesis contributes to the pathogenesis of inflammatory bowel disease (IBD). In line with this, the efficacy of inhibitors of angiogenesis has been demonstrated in experimental models of colitis. Currently, the ability of infliximab, an anti-tumor necrosis...

  • Levels of Anti-Double-Strained DNA but not Antinuclear Antibodies are Associated with Treatment Efficacy and Adverse Outcomes in Crohn's Disease Patients Treated with anti-TNFα. Kiss, Lajos S.; Lovasz, Barbara D.; Golovics, Petra A.; Vegh, Zsuzsanna; Farkas, Klaudia; Molnar, Tamas; Palatka, Karoly; Papp, Maria; Mohas, Anna; Szilagyi, Blanka K.; Fekete, Szandra A.; Mandel, Michael; Lakatos, Peter L. // Journal of Gastrointestinal & Liver Diseases;Jun2013, Vol. 22 Issue 2, p135 

    Background & Aims: Treatment of Crohn's disease (CD) by infliximab (IFX) has been associated with the induction of antinuclear (ANA) and anti-double strand DNA (d5DNA) autoantibodies and in some studies the formation of dsDNA antibodies was associated with lupus-like syndromes. The aims of this...

  • Biologic response modifiers to decrease inflammation: Focus on infection risks. Saux, Nicole Le // Paediatrics & Child Health (1205-7088);Mar2012, Vol. 17 Issue 3, p147 

    Biologic response modifiers are a novel class of drugs used by sub-specialists to treat immune-mediated conditions such as juvenile idiopathic arthritis and inflammatory bowel disease. Also known as 'cytokine inhibitors', they are proteins whose purpose is to block the action of cytokines...

  • The classics in perspective. Panés, Julián; Ghosh, Subrata // Gut;Sep2007, Vol. 56 Issue 9, p1184 

    The authors reflect on the development of anti-cytokine therapies as biological agents in treating Crohn's disease and inflammatory diseases. Their therapeutic approach to these diseases has expanded. They noted that gastroenterologists face a remarkable wave of new biological therapies for...


Read the Article


Sign out of this library

Other Topics